NeuroLogica received the European CE Mark for the inSPira HD SPECT system. The battery powered system received U.S. FDA approval two years ago. It can be moved between different hospital units as needed and provides a look at cerebral blood flow distribution in patients with Alzheimer’s, epilepsy, post-stroke and other conditions.NeuroLogica claims that proprietary technology within its SPECT camera provides a considerably higher spatial resolution than any other SPECT on the market.
More from the announcement:
Designed primarily for brain imaging, the battery-powered inSPira HD™ can provide high-quality SPECT images in any venue, including epilepsy clinics, ICUs and private practice neurological imaging centers. The high-resolution camera is capable of imaging any radioisotope energies between 80-200 keV for clinical applications such as epilepsy, Parkinson’s disease, neuropsychology, stroke and brain perfusion as well as Alzheimer’s disease and dementia. “Features such as high spatial resolution, convenience, portability and versatility set the inSPira HD™ apart from other brain SPECT imaging systems currently on the American and European markets,” said Dr. Colin Timothy McDonald, NeuroLogica’s chief medical officer. “The technologies in traditional systems haven’t really changed since the 1960s so they continue to suffer from poor spatial and contrast resolution, in short, ‘fuzzy imaging.'” The inSPira HD™ presents a new method of SPECT detection, acquisition and reconstruction, which is designed to approach a spatial resolution of 3mm, rivaling that of PET imaging.